about
Immunomodulation of cancer: potential use of selectively replicating agents.Regulatable systems: applications in gene therapy and replicating viruses.Gene therapy: development of immunostimulatory treatments for cancer.Cell-free tumor antigen peptide-based cancer vaccinesMagnetic nanoparticles as targeted delivery systems in oncology.Comparison of the Calibration Standards of Three Commercially Available Multiplex Kits for Human Cytokine Measurement to WHO Standards Reveals Striking Differences.Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: a novel general strategy for the generation of potent cancer vaccines.Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels.The combined effect against colon-26 cells of heat treatment and immunization with heat treated colon-26 tumour cell extract.Development of transferrin-polycation/DNA based vectors for gene delivery to melanoma cells.Tumor immunotherapy by vaccination with cytokine gene transfected cells.Immunobiology of gliomas: new perspectives for therapy.DNA cancer vaccines: a gene gun approach.A novel amino acid supplementation strategy based on a stoichiometric model to enhance human IL-2 (interleukin-2) expression in high-cell-density Escherichia coli cultures.Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators.Dose of adenoviral vectors expressing interleukin-2 plays an important role in combined gene therapy with cytosine deaminase/5-fluorocytosine: preclinical consideration.Replication-defective recombinant Semliki Forest virus encoding GM-CSF as a vector system for rapid and facile generation of autologous human tumor cell vaccines.Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.Cytokines and cancer.Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
P2860
Q33904276-ED99EF6D-B05A-428B-A3F4-9B07AB3853E3Q33904282-83E04293-DBC2-4A62-8E16-FC82FEA9DC6DQ34187915-A5A7D69A-0986-426A-A172-613416364161Q36084122-CC5F97A6-53FC-4812-B661-96A281232A9FQ36177729-29B18444-4366-4B3C-947B-19D9EA82B9C3Q37207300-A5F8C742-2E8B-471A-BF94-211F68EA1BCCQ37362679-46368D6B-6422-4232-9148-91F946EC9194Q40744502-DFCC8B79-9B3B-426B-9345-5A33E281F3DDQ40877081-5C610ABD-976C-4E5E-BBEF-CE301EE81BC4Q40899216-49624219-0EE6-4003-A5B6-AA6DE964D38AQ41455939-3C05D994-697F-4515-A92A-8AAAFC4BBA75Q41650683-9FAB56A5-15D6-44D3-9236-9A4F0FBFD5D9Q41682341-7A56B633-D514-4FB7-8FC9-A68AFCBE5F1EQ42826573-505F8ED6-25D2-4280-9049-EEB0E9DA8A43Q44021835-089FB252-36DD-4877-8231-B174A85FF58BQ44038362-5FB0AAA7-0C52-43E8-88AE-26933F9A9244Q45734835-FDD1E52A-4399-4BEA-9412-D4437779D360Q46990195-38D08B17-25F0-4E6F-BF4A-EB3A899C3D91Q47912519-15137FE0-DF53-4413-96BE-E37E978D0F65Q56966393-2CD46AC6-15AB-4CBF-8B55-E7BAC2C61546
P2860
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Cancer vaccines: the interleukin 2 dosage effect
@ast
Cancer vaccines: the interleukin 2 dosage effect
@en
Cancer vaccines: the interleukin 2 dosage effect
@nl
type
label
Cancer vaccines: the interleukin 2 dosage effect
@ast
Cancer vaccines: the interleukin 2 dosage effect
@en
Cancer vaccines: the interleukin 2 dosage effect
@nl
prefLabel
Cancer vaccines: the interleukin 2 dosage effect
@ast
Cancer vaccines: the interleukin 2 dosage effect
@en
Cancer vaccines: the interleukin 2 dosage effect
@nl
P2093
P2860
P356
P1476
Cancer vaccines: the interleukin 2 dosage effect
@en
P2093
Birnstiel ML
Schaffner G
Schilcher F
Schweighoffer T
P2860
P304
P356
10.1073/PNAS.92.10.4711
P407
P577
1995-05-01T00:00:00Z